We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Skin cancers are the most common groups of cancers diagnosed worldwide.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermato-oncology.
Meet our team of experts dedicated to pioneering breakthroughs in therapeutics. Their unparalleled expertise & passion drive our mission to transform dermato-oncology.
BO-112 monotherapy
A Multicenter, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High-Risk Basal Cell Carcinoma.
Independent
